Bussel et a1 also make observations concerning the safety of the Winrho anti-D Ig that we think could be misleading. All the original IgG preparations for intramuscular use were manufactured by simple Cohn ethanol fractionation and contained polymeric IgG. Although these caused severe adverse reactions when administered intravenously to patients with hypogammaglobulinemia, this was not so in subjects with normal levels of IgG.9
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Most anti (Rh)-D immunoglobulins are manufactured for intramuscular use, but we have now safely administered such preparations by slow intravenous infusion to over 50 patients with AITP without adverse reactions. This contrasts with the five severe reactions described by Bussel Moise et al' was a pregnant woman who had had ITP diagnosed years before the pregnancy. At 26 weeks of gestation she was begun on 40 mg of prednisone per day; 4 weeks later she received anti-D IV 120 mcg. Three weeks later she was found to have a platelet count 30,000/kL higher that then returned to the preinfusion range for the next four counts until delivery. Platelet counts fluctuate considerably in ITP in pregnant women, and the lack of repeated responsiveness makes it difficult to attribute this patient's response to the coincidentally administered anti-D. In contrast, at least 7 Rh-ITP patients have been treated with anti-D to increase platelet counts and all of those patients of Salama et a1,8 Oksenhendler et a1,9 and ourselves had no platelet response at all, in contrast to the majority of Rh' patients. Of interest, the three Rh-patients of Oksenhendler et alY were subsequently treated with plasma containing anti-"c" and anti-"e" and all three responded, confirming the requirement for specific anti-red cell antibody for therapeutic efficacy in ITP. This demonstrates that antibodycoated red cells are important for the efficacy of anti-D treatment of ITP, although it does not exclude an additional effect of the IgG aggregates. We assume that this is also the conclusion of Boughton et a1 because they stated in 1990"': "There are, to our knowledge, five rhesus-negative patients who have been treated with anti-D and none has shown a therapeutic response. This supports the role of opsonized RBC's in the induction of MPS FcR blockade in ITP."
A final point addresses the issue of long-term response to treatment. As Boughton alludes to, there are many anecdotal, a few systematic,"," but no controlled studies of whether gammaglobulin infusion has any curative effect in patients with ITP. In the cases of apparent long-term responses, it is currently fashionable to think that these are due to the development of (or infusion of) anti-idiotypic antib~dies.'~ We believe that there may also be a role for FcR-mediated effects, so-called immunomodulatory effects of 
